Joanne L. Blum
YOU?
Author Swipe
View article: Treatment of infertility and risk of breast cancer among women with a BRCA pathogenic variant: a matched case-control study
Treatment of infertility and risk of breast cancer among women with a BRCA pathogenic variant: a matched case-control study Open
View article: Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARIS
Real-world effectiveness of palbociclib plus hormone treatment and its impact on patient quality of life: a plain language summary of findings from POLARIS Open
What is this summary about?
View article: Enhancing the interpretation of real-world quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer enrolled in the POLARIS study
Enhancing the interpretation of real-world quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer enrolled in the POLARIS study Open
Importance Patient-reported outcomes are recommended clinical outcome assessments of quality of life (QoL) by patient advocacy groups and regulatory agencies to gain a better understanding of treatment effectiveness, tolerability and safet…
View article: Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study
Circulating Tumor DNA Genotyping of Intrinsic and Acquired Gene Alterations in Patients With Advanced Breast Cancer Receiving Palbociclib: Biomarker Results From POLARIS Study Open
PURPOSE To identify gene alterations in circulating tumor DNA (ctDNA) from palbociclib-treated patients with advanced or metastatic breast cancer (ABC) in POLARIS to identify potential mutagenic drivers of resistance. METHODS POLARIS was a…
View article: Boundaries
Boundaries Open
View article: Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS
Real-world quality-of-life of patients with HR+/HER2− advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS Open
View article: Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2− advanced breast cancer: final results from the POLARIS trial
Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2− advanced breast cancer: final results from the POLARIS trial Open
Background Strict eligibility criteria for participation in randomized clinical trials (RCTs) often limit the generalizability of data when applied to a more heterogeneous real-world population. Thus, evidence generated directly from real-…
View article: Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status
Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status Open
View article: Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology])
Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]) Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study Open
View article: 373P Impact of comorbidities on real-world (rw) clinical outcomes of patients (pts) with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) treated with palbociclib and enrolled in POLARIS
373P Impact of comorbidities on real-world (rw) clinical outcomes of patients (pts) with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) treated with palbociclib and enrolled in POLARIS Open
View article: 461P Impact of comorbidities on real-world patient-reported outcomes of patients (pts) with hormone receptor-positive human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) enrolled in the POLARIS trial
461P Impact of comorbidities on real-world patient-reported outcomes of patients (pts) with hormone receptor-positive human epidermal growth factor 2-negative (HR+/HER2-) advanced breast cancer (ABC) enrolled in the POLARIS trial Open
View article: On grief, ghosts, and gallantry
On grief, ghosts, and gallantry Open
"On grief, ghosts, and gallantry." Baylor University Medical Center Proceedings, 36(6), pp. 770–771 Disclosure statement/FundingThe author reports no funding or conflicts of interest.
View article: Supplementary Table 4 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 4 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 42K, Ingenuity Canonical Pathways results for mTNBC based on edgeR differential expression results
View article: Supplementary Table 8 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 8 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 273K, Somatic genic focal copy number changes in mTNBC
View article: Data from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Data from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
Triple-negative breast cancer (TNBC) is characterized by the absence of expression of estrogen receptor, progesterone receptor, and HER-2. Thirty percent of patients recur after first-line treatment, and metastatic TNBC (mTNBC) has a poor …
View article: Supplementary Figure 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Figure 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
PDF file - 1635K, PET/CT images of mTNBC2 breast lesion before and after treatment on combination MEK and AKT inhibitors
View article: Supplementary Table 7 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 7 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 61K, List of somatic point mutations in mTNBC detected by NGS sequencing analysis
View article: Supplementary Table 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 598K, edgeR differential expression results in mTNBC for select cancer related genes
View article: Supplementary Table 6 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 6 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 23K, Mapping statistics for genome sequencing of tumor and germline DNA from mTNBC
View article: Supplementary Figure 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Figure 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
PDF file - 72K, Profiles of germline/tumor single base mutations by genotype in mTNBC
View article: Supplementary Table 9 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 9 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 45K, Genes containing breakpoint from translocation in mTNBC
View article: Supplementary Table 5 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 5 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 607K, Outlier differential expression results in mTNBC for select cancer related genes
View article: Supplementary Figure 2 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Figure 2 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
PDF file - 135K, Validation of RB1 39bp homozygous deletion in mTNBC1
View article: Supplementary Table 8 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 8 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 273K, Somatic genic focal copy number changes in mTNBC
View article: Supplementary Table 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 1 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 40K, Characteristics of mTNBC study population
View article: Supplementary Table 7 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 7 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 61K, List of somatic point mutations in mTNBC detected by NGS sequencing analysis
View article: Supplementary Table 5 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 5 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 607K, Outlier differential expression results in mTNBC for select cancer related genes
View article: Supplementary Table 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Supplementary Table 3 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
XLSX file - 598K, edgeR differential expression results in mTNBC for select cancer related genes
View article: Data from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Data from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities Open
Triple-negative breast cancer (TNBC) is characterized by the absence of expression of estrogen receptor, progesterone receptor, and HER-2. Thirty percent of patients recur after first-line treatment, and metastatic TNBC (mTNBC) has a poor …